Niche offering Early-stage lung cancer blood test targeting high-risk smokers and former smokers over 50 presents a focused product with clear clinical value, ideal for outreach to oncology clinics, primary care groups, and smoking cessation programs seeking preventive diagnostics.

Affordability signal Priced at 99 plus shipping, the test’s accessible price point can be leveraged in value-based discussions with payers, clinics, and diagnostic networks looking to expand screening without substantial cost barriers.

Clinical validation Clinical study backing for early-stage lung cancer risk assessment can be highlighted in sales pitches to hospitals, cancer centers, and research-oriented labs seeking validated diagnostic tools.

Small company leverage With a very small team, partnerships with larger contract manufacturers, distributors, or clinical research organizations could accelerate deployment, channel strategies, and market reach without headcount expansion.

Market positioning Position alongside established oncology diagnostics players as a complementary screening option for high-risk populations, targeting business development conversations with large multifunctional labs and genomics service providers.